Improving breast cancer treatments using pharmacomicrobiomics
ABSTRACT Tamoxifen is the mainstay treatment for estrogen-positive breast cancer for over half a century. However, a significant proportion of patients experience disease recurrence due to treatment failure attributed to various factors, including disease pathology, genetics, and drug metabolism. Al...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
American Society for Microbiology
2025-02-01
|
| Series: | mBio |
| Subjects: | |
| Online Access: | https://journals.asm.org/doi/10.1128/mbio.03422-24 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832096539667857408 |
|---|---|
| author | Aswin Anand Pai Aadra Prashant Bhatt |
| author_facet | Aswin Anand Pai Aadra Prashant Bhatt |
| author_sort | Aswin Anand Pai |
| collection | DOAJ |
| description | ABSTRACT Tamoxifen is the mainstay treatment for estrogen-positive breast cancer for over half a century. However, a significant proportion of patients experience disease recurrence due to treatment failure attributed to various factors, including disease pathology, genetics, and drug metabolism. Alam et al. introduce gut microbiota as a key factor influencing tamoxifen pharmacokinetics (Y. Alam, S. Hakopian, L. Ortiz de Ora, I. Tamburini, et al., mBio 16:e01679-24, 2024, https://doi.org/10.1128/mbio.01679-24). The authors present compelling evidence that functional differences in the gut microbiota, specifically the bacterial enzyme β-glucuronidase, leads to inter-individual variability in systemic exposure of tamoxifen, affecting drug efficacy. This study provides novel insights into the impact of the gut microbiota on tamoxifen pharmacokinetics, the latest example of how pharmacomicrobiomics, or the study of drug-microbe interactions, can enhance precision medicine for numerous diseases. |
| format | Article |
| id | doaj-art-c964b8973cc647ada4036d275bee24a9 |
| institution | Kabale University |
| issn | 2150-7511 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | American Society for Microbiology |
| record_format | Article |
| series | mBio |
| spelling | doaj-art-c964b8973cc647ada4036d275bee24a92025-02-05T14:00:47ZengAmerican Society for MicrobiologymBio2150-75112025-02-0116210.1128/mbio.03422-24Improving breast cancer treatments using pharmacomicrobiomicsAswin Anand Pai0Aadra Prashant Bhatt1Department of Haematology, Christian Medical College, Vellore, IndiaCenter for Gastrointestinal Biology and Disease and Department of Medicine, Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USAABSTRACT Tamoxifen is the mainstay treatment for estrogen-positive breast cancer for over half a century. However, a significant proportion of patients experience disease recurrence due to treatment failure attributed to various factors, including disease pathology, genetics, and drug metabolism. Alam et al. introduce gut microbiota as a key factor influencing tamoxifen pharmacokinetics (Y. Alam, S. Hakopian, L. Ortiz de Ora, I. Tamburini, et al., mBio 16:e01679-24, 2024, https://doi.org/10.1128/mbio.01679-24). The authors present compelling evidence that functional differences in the gut microbiota, specifically the bacterial enzyme β-glucuronidase, leads to inter-individual variability in systemic exposure of tamoxifen, affecting drug efficacy. This study provides novel insights into the impact of the gut microbiota on tamoxifen pharmacokinetics, the latest example of how pharmacomicrobiomics, or the study of drug-microbe interactions, can enhance precision medicine for numerous diseases.https://journals.asm.org/doi/10.1128/mbio.03422-24microbiomeprecision medicinepharmacomicrobiomics |
| spellingShingle | Aswin Anand Pai Aadra Prashant Bhatt Improving breast cancer treatments using pharmacomicrobiomics mBio microbiome precision medicine pharmacomicrobiomics |
| title | Improving breast cancer treatments using pharmacomicrobiomics |
| title_full | Improving breast cancer treatments using pharmacomicrobiomics |
| title_fullStr | Improving breast cancer treatments using pharmacomicrobiomics |
| title_full_unstemmed | Improving breast cancer treatments using pharmacomicrobiomics |
| title_short | Improving breast cancer treatments using pharmacomicrobiomics |
| title_sort | improving breast cancer treatments using pharmacomicrobiomics |
| topic | microbiome precision medicine pharmacomicrobiomics |
| url | https://journals.asm.org/doi/10.1128/mbio.03422-24 |
| work_keys_str_mv | AT aswinanandpai improvingbreastcancertreatmentsusingpharmacomicrobiomics AT aadraprashantbhatt improvingbreastcancertreatmentsusingpharmacomicrobiomics |